ArticleInfection2015
Evaluation of the NanoCHIP® Infection Control Panel test for direct detection and screening of methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria and vancomycin-resistant Enterococcus (VRE).
Article in Infection, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRapid detection of infection control targets is needed and several bacterial target assays are commercially available. Detection of patients colonized with Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae (KPC-CRE), methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) comprises an essential part of infection control programs. This study evaluated the performance and feasibility of a novel molecular-based diagnostic screening test, the NanoCHIP(®) Infection Control Panel (ICP) assay (Savyon Diagnostics, Israel), which enables simultaneous detection of KPC-CRE, MRSA and VRE directly from swab samples and compares its sensitivity and specificity to culture.
methodsProspective direct swab analysis of 338 (70 CRE, 198 MRSA and 70 VRE) screening swab samples.
resultsIncluding all targets and all valid samples, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the NanoCHIP(®) ICP assay were 91.1, 99.5, 99.1 and 94.9 %, respectively.
conclusionsAs far as we know, this is the first report regarding a single molecular-based system that detects all three targets (CRE-KPC, MRSA and VRE) simultaneously, directly from swab samples, using the same reaction and platform. Overall, the assay was easy to perform, enabling medium- to high-throughput screening. Same day results enable efficient infection control interventions, such as carrier isolation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.